Literature DB >> 7689036

A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines.

S V Garde1, A R Sheth, A T Porter, K J Pienta.   

Abstract

Prostatic inhibin peptide (PIP), consisting of 94 amino-acid residues is synthesized and secreted by the prostate gland. Previous studies on immunohistochemical localization of PIP in primary prostatic tumor and their metastasis, have documented the value of this peptide as a tumor marker for diagnosis of prostate cancer (PCa). The present study was undertaken to compare the expression of PIP with that of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in androgen independent human PCa cell lines (PC-3, DU-145 and TSU-Prl) by immunoperoxidase technique. The results of the study indicated that the staining for PIP was more intense than that of PSA and PAP. The PSA staining was either weakly positive (PC-3) or totally absent (TSU-Prl and DU-145) while PAP staining was intense in PC-3 and moderate in the other two human cell lines. The intense staining observed for PIP in all of the androgen independent cell lines suggests that the synthesis and secretion of PIP is not primarily dependent on androgens. Furthermore, expression of these markers in Dunning rat cultured adenocarcinoma cell lines and tumors were studied. Positive staining for all three human tumor associated antigens (PIP, PSA and PAP) cross-reacting with the Dunning rat PCa cell lines and the tumors, suggest the suitability of this model for preclinical screening of various therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689036     DOI: 10.1016/0304-3835(93)90226-y

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Characterization of ostrich (Struthio camelus) beta-microseminoprotein (MSP): identification of homologous sequences in EST databases and analysis of their evolution during speciation.

Authors:  C Lazure; M Villemure; D Gauthier; R J Naudé; M Mbikay
Journal:  Protein Sci       Date:  2001-11       Impact factor: 6.725

2.  Development of the VCaP androgen-independent model of prostate cancer.

Authors:  Robert D Loberg; Lauren N St John; LaShon L Day; Chris K Neeley; Kenneth J Pienta
Journal:  Urol Oncol       Date:  2006 Mar-Apr       Impact factor: 3.498

3.  Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.

Authors:  Liisa Sjöblom; Outi Saramäki; Matti Annala; Katri Leinonen; Janika Nättinen; Teemu Tolonen; Tiina Wahlfors; Matti Nykter; G Steven Bova; Johanna Schleutker; Teuvo L J Tammela; Hans Lilja; Tapio Visakorpi
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.